Cervical cancer is a significant health concern in Thailand, as it is in many other parts of the world. According to the National Cancer Institute’s statistics from 2010, cervical cancer is the second most common form of cancer among women in Thailand, with breast cancer being the most common. This underscores the importance of regular cervical cancer screenings and early detection to prevent the disease from progressing to more advanced stages.
It is important for women to understand the risk factors for cervical cancer, including certain strains of the human papillomavirus (HPV), smoking, and a weakened immune system, and to take steps to reduce those risks whenever possible. This may include getting vaccinated against HPV, quitting smoking, and practicing safe sex.
In addition to reducing individual risk factors, it is important for policymakers and healthcare providers in Thailand to prioritize efforts to improve access to cervical cancer screenings and treatment options, particularly for underserved populations. This could include expanding outreach and education efforts to raise awareness of the importance of early detection, as well as increasing funding for cervical cancer research and treatment programs. With a comprehensive approach that includes both prevention and early detection, it may be possible to reduce the incidence and mortality of cervical cancer in Thailand over time.
Facts about HPV (Human papillomavirus)
- Sexually active women have a high likelihood of being infected with HPV at some point in their lives, as HPV is a very common sexually transmitted infection. However, in the majority of cases, the body’s immune system will clear the infection within 1-2 years without causing any further symptoms or disease.
- Using a condom during sexual intercourse can reduce the risk of HPV transmission, but it does not offer complete protection, as HPV can be transmitted through skin-to-skin contact in the genital area. Additionally, even individuals with only one sexual partner can still be at risk of HPV infection, as the virus can remain dormant in the body for years before causing symptoms.
- Regular screening for HPV is important for sexually active women, as it can detect the presence of the virus before it causes any symptoms or develops into a more serious condition, such as cervical cancer. The recommended screening interval and method may vary depending on age and other risk factors, so it’s best to consult with a healthcare provider for personalized recommendations.
What are the main causes of Cervical Cancer?
- The Human Papilloma Virus (HPV) is the main cause of cervical cancer, and certain high-risk types of HPV, such as types 16 and 18, are associated with a higher risk of developing cervical cancer. HPV-16 is the most common type found in cervical cancer cases, followed by HPV-18.
- Adenocarcinoma is a type of cervical cancer that originates in the glandular cells of the cervix and is less common than squamous cell carcinoma, which originates in the flat, thin cells lining the outer part of the cervix. Adenocarcinoma has a higher chance of being missed by a Pap smear screening alone, which is why co-testing using the Pap test and HPV test is recommended for women aged 30 years and older.
- The Pap test looks for abnormal cells in the cervix, while the HPV test looks for the presence of high-risk types of HPV. Co-testing has been found to be more effective than either test alone in detecting cervical cancer and precancerous lesions. The American Society of Colposcopy and Cervical Pathology (ASCCP) recommends co-testing every five years for women aged 30 to 65 years.
Importance of PAP and HPV Co-Testing
- The use of co-testing with both Pap smear and HPV testing has become the preferred method for cervical cancer screening in many countries, including the United States. HPV testing can detect the presence of high-risk types of the human papillomavirus that can cause cervical cancer, even before abnormal cells are visible on a Pap smear. Combining both tests can increase the sensitivity and specificity of cervical cancer screening and reduce the frequency of false-negative results.
- The American Cancer Society recommends that women aged 25 to 65 years should undergo co-testing every five years, or Pap testing alone every three years. Women under 25 years of age or older than 65 years may not need to undergo screening if they have no history of abnormal Pap or HPV test results.
- It is important to note that while co-testing provides greater accuracy and certainty, it does not guarantee that a person will not develop cervical cancer. Regular screening and follow-up care are still necessary to detect and treat any abnormalities or precancerous changes as early as possible.
